| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3366760 | Joint Bone Spine | 2010 | 5 Pages |
Abstract
Infliximab was effective, safe and well-tolerated in patients with ankylosing spondylitis. The clinical response was maintained for a period of 6Â years, with high infliximab survival rate, reaching the percentage of 72.5%.
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Ioanna Saougou, Theodora E. Markatseli, Paraskevi V. Voulgari, Alexandros A. Drosos,